{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:24:54Z","timestamp":1777922694262,"version":"3.51.4"},"reference-count":38,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2013,11,22]],"date-time":"2013-11-22T00:00:00Z","timestamp":1385078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2014,4,1]]},"abstract":"<jats:p>\n                    <jats:bold>\n                      <jats:italic toggle=\"yes\">Aim:<\/jats:italic>\n                    <\/jats:bold>\n                    We studied the serotypes and antimicrobial resistance of the invasive\n                    <jats:italic toggle=\"yes\">Streptococcus pneumoniae<\/jats:italic>\n                    that had been isolated in Finland during 5 years. The 10-valent vaccine was introduced into the National Vaccination Programme in September 2010.\n                    <jats:bold>\n                      <jats:italic toggle=\"yes\">Methods:<\/jats:italic>\n                    <\/jats:bold>\n                    We examined the antimicrobial resistance and serotype distribution of the invasive pneumococci (\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    =4,194) that had been isolated in Finland during 2007\u20132011. The penicillin-resistant (PEN R) (\u22654\u2009mg\/L) isolates (\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    =12) were genotyped by MLST.\n                    <jats:bold>\n                      <jats:italic toggle=\"yes\">Results:<\/jats:italic>\n                    <\/jats:bold>\n                    Serotype 14 was consistently the most prominent serotype, covering 18.0\u201320.1% of all the isolates. The proportion of serotypes 3, 19A, and 22F increased significantly, while that of 6B and the PCV10 vaccine serotypes combined decreased. PEN nonsusceptibility (\u22650.12\u2009mg\/L) increased, ranging from 14.4% to 23.2% by year, and was the highest (28.5%) among the 0\u20132 year olds. The PEN and\/or erythromycin (ERY) nonsusceptibility of several vaccine serotypes (4, 6B, 14, and 19F) increased significantly over the study period. The ERY nonsusceptibility was 26.6%. There was limited diversity among the PEN R isolates; all were a part of serotype 19F, 19A, or 14, and two globally disseminated genetic lineages carrying one or both pilus-encoding islets.\n                    <jats:bold>\n                      <jats:italic toggle=\"yes\">Conclusions:<\/jats:italic>\n                    <\/jats:bold>\n                    High and\/or increasing nonsusceptibility rates underline the importance of monitoring the serotype distribution and antimicrobial susceptibility of pneumococci, especially after large-scale vaccination.\n                  <\/jats:p>","DOI":"10.1089\/mdr.2013.0156","type":"journal-article","created":{"date-parts":[[2013,11,22]],"date-time":"2013-11-22T10:49:57Z","timestamp":1385117397000},"page":"124-130","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Antimicrobial Resistance in Relation to Sero- and Genotypes Among Invasive\n                    <i>Streptococcus pneumoniae<\/i>\n                    in Finland, 2007\u20132011"],"prefix":"10.1177","volume":"20","author":[{"given":"Lotta","family":"Siira","sequence":"first","affiliation":[{"name":"National Institute for Health and Welfare","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jari","family":"Jalava","sequence":"additional","affiliation":[{"name":"National Institute for Health and Welfare","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarja","family":"Kaijalainen","sequence":"additional","affiliation":[{"name":"National Institute for Health and Welfare","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jukka","family":"Ollgren","sequence":"additional","affiliation":[{"name":"National Institute for Health and Welfare","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Outi","family":"Lyytik\u00e4inen","sequence":"additional","affiliation":[{"name":"National Institute for Health and Welfare","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anni","family":"Virolainen","sequence":"additional","affiliation":[{"name":"National Institute for Health and Welfare","place":["Finland"]},{"name":"Ministry of Social Affairs and Health","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2013,11,22]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.00384-08"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0511017103"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir052"},{"key":"e_1_3_3_5_2","unstructured":"[CLSI] Clinical and Laboratory Standards Institute.. 2005. Performance standards for antimicrobial susceptibility testing: 15th informational supplement. Clinical and Laboratory Standards Institute Pennsylvania."},{"key":"e_1_3_3_6_2","unstructured":"[CLSI] Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing: 18th informational supplement. CLSI document M100-S18. Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/597044"},{"key":"e_1_3_3_8_2","unstructured":"[EUCAST] European Committee on Antimicrobial Susceptibility Testing. 2013. Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 3.0 Available at www.eucast.org (Online.)"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01454-08"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00830-12"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.epidem.2010.03.005"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/649872"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181c15471"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/592972"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-1702"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365540801938931"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051642"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1086\/521831"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05122-11"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1202939"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2008.0782"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2009.0056"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01475-06"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61854-6"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365548.2011.652162"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31803df9ca"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf033"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1086\/648593"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr048"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-011-1386-8"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00689-12"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01464-08"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0705589104"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71043-6"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-010-1112-y"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.12.054"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.05563-11"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-12-207"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022823"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2013.0156","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2013.0156","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2013.0156","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:28:06Z","timestamp":1777667286000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/mdr.2013.0156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,22]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4,1]]}},"alternative-id":["10.1089\/mdr.2013.0156"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2013.0156","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,22]]}}}